Circulating Levels of Adipocyte and Epidermal Fatty Acid–Binding Proteins in Relation to Nephropathy Staging and Macrovascular Complications in Type 2 Diabetic Patients

  1. Dennis C.Y. Yeung, BSC12,
  2. Aimin Xu, PHD123,
  3. Annette W.K. Tso, MD12,
  4. W.S. Chow, MD1,
  5. Nelson M.S. Wat, MD1,
  6. Carol H.Y. Fong, BSC1,
  7. Sidney Tam, MD4,
  8. Pak C. Sham, MD5 and
  9. Karen S.L. Lam, MD12
  1. 1Department of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China
  2. 2Research Centre of Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China
  3. 3Department of Pharmacology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China
  4. 4Clinical Biochemistry Unit, Queen Mary Hospital, Hong Kong, China
  5. 5Department of Psychiatry, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China
  1. Corresponding author: Karen S.L. Lam, ksllam{at}hkucc.hku.hk

Abstract

OBJECTIVE—To investigate the relationships of serum adipocyte fatty acid–binding protein (A-FABP) and epidermal fatty acid–binding protein (E-FABP) with renal dysfunction and macrovascular complications in type 2 diabetic patients.

RESEARCH DESIGN AND METHODS—The associations of serum A-FABP and E-FABP with markers of renal function, nephropathy staging, and macrovascular complications were examined in 237 type 2 diabetic patients.

RESULTS—Serum A-FABP and E-FABP correlated significantly with serum creatinine, mean albumin excretion rate, and glomerular filtration rate (all P < 0.001) and were independently associated with diabetic nephropathy staging (P = 0.001 and P < 0.05, respectively). Circulating levels of both types of FABP were increased (P < 0.01) in subjects with macrovascular complications. Serum A-FABP was independently associated with macrovascular complications (odds ratio 2.92 [95% CI 1.42–6.01]; P = 0.004).

CONCLUSIONS—Serum A-FABP and E-FABP might be novel serum biomarkers for evaluating the progression of nephropathy and its cardiovascular risk in type 2 diabetic patients.

Footnotes

  • Published ahead of print at http://care.diabetesjournals.org on 17 October 2008.

    Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

    • Accepted October 8, 2008.
    • Received July 18, 2008.
« Previous | Next Article »Table of Contents

This Article

  1. Published online before print October 17, 2008, doi: 10.2337/dc08-1333 Diabetes Care January 2009 vol. 32 no. 1 132-134
  1. » Abstract
  2. Full Text
  3. Full Text (PDF)
  4. Online-Only Appendix
  5. All Versions of this Article:
    1. dc08-1333v1
    2. 32/1/132 most recent

Current Issue

  1. December 2009, 32 (12)
  1. Current Issue
  1. Alert me to new issues of Diabetes Care